HomeCompareVWE vs ABBV

VWE vs ABBV: Dividend Comparison 2026

VWE yields 7633.59% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VWE wins by $3875175132855487.00M in total portfolio value
10 years
VWE
VWE
● Live price
7633.59%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3875175132855487.00M
Annual income
$3,777,821,861,873,786,600,000.00
Full VWE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VWE vs ABBV

📍 VWE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVWEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VWE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VWE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VWE
Annual income on $10K today (after 15% tax)
$648,854.96/yr
After 10yr DRIP, annual income (after tax)
$3,211,148,582,592,718,600,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VWE beats the other by $3,211,148,582,592,718,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VWE + ABBV for your $10,000?

VWE: 50%ABBV: 50%
100% ABBV50/50100% VWE
Portfolio after 10yr
$1937587566427743.50M
Annual income
$1,888,910,930,936,893,300,000.00/yr
Blended yield
97.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VWE
Analyst Ratings
2
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$3.50
+13258.8% upside vs current
Range: $3.50 — $3.50
Altman Z
-1.2
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VWE buys
0
ABBV buys
0
No recent congressional trades found for VWE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVWEABBV
Forward yield7633.59%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3875175132855487.00M$102.3K
Annual income after 10y$3,777,821,861,873,786,600,000.00$24,771.77
Total dividends collected$3868663309457101.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$3.50$256.15

Year-by-year: VWE vs ABBV ($10,000, DRIP)

YearVWE PortfolioVWE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$774,059$763,358.78$11,550$430.00+$762.5KVWE
2$56,051,099$55,222,856.43$13,472$627.96+$56.04MVWE
3$3,797,165,586$3,737,190,909.47$15,906$926.08+$3797.15MVWE
4$240,675,043,959$236,612,076,782.26$19,071$1,382.55+$240675.02MVWE
5$14,273,540,518,079$14,016,018,221,042.54$23,302$2,095.81+$14273540.49MVWE
6$792,130,483,903,219$776,857,795,548,874.50$29,150$3,237.93+$792130483.87MVWE
7$41,139,945,128,991,770$40,292,365,511,215,320.00$37,536$5,121.41+$41139945128.95MVWE
8$1,999,736,551,228,926,500$1,955,716,809,940,905,000.00$50,079$8,338.38+$1999736551228.88MVWE
9$90,984,365,403,458,080,000$88,844,647,293,643,130,000.00$69,753$14,065.80+$90984365403458.02MVWE
10$3,875,175,132,855,487,000,000$3,777,821,861,873,786,600,000.00$102,337$24,771.77+$3875175132855487.00MVWE

VWE vs ABBV: Complete Analysis 2026

VWEStock

Vintage Wine Estates, Inc. produces and sells wines and craft spirits in the United States, Canada, and internationally. The company offers its products under the Layer Cake, Firesteed, Bar Dog, Middle Sister, Cherry Pie, Cartlidge & Browne, GAZE Wine Cocktails, Girard, Clos Pegase, Laetitia Vineyard and Winery, Swanson Vineyards, Kunde Family Winery, Viansa, and B.R. Cohn Winery. It also owns and operates hospitality facilities; and provides bottling, fulfillment, and storage services to other companies on a contract basis. The company was founded in 2019 and is headquartered in Incline Village, Nevada.

Full VWE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VWE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VWE vs SCHDVWE vs JEPIVWE vs OVWE vs KOVWE vs MAINVWE vs JNJVWE vs MRKVWE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.